No Data
No Data
Atomo Diagnostics Advances Australia-Wide HIV Self-Test Kit Rollout; Shares Rise 4%
Atomo Diagnostics (ASX:AT1) advanced the Australia-wide rollout of its HIV self-test kit supported by both federal and state governments, according to a Wednesday filing with the Australian bourse. Th
Guess Which ASX Healthcare Stock Just Exploded 63% on Federal Budget Funding News!
An under-the-radar ASX healthcare stock is rocketing today.
Atomo Diagnostics Supports HIV-Self Testing Push of the Australian Federal Government; Shares Surge 19%
Atomo Diagnostics (ASX:AT1) supported the Australian federal government's push to end HIV transmissions by 2030 following an expanded funding commitment to the national HIV self-testing program, accor
Atomo Diagnostics Boosted by Federal Funding for HIV Prevention and Self-test Expansion
Medical device company Atomo Diagnostics (ASX: AT1) has welcomed the Australian government’s commitment to fund the expansion of self-testing procedures for human immunodeficiency virus (HIV) in this week’s federal budget.
Atomo Diagnostics Wins AU$570,000 HIV Self-Tests Order
Atomo Diagnostics (ASX:AT1) secured purchase orders valued at AU$570,000 from Viatris Healthcare for Mylan HIV self-tests, according to a Monday filing with the Australian bourse. The orders will be m
Atomo Diagnostics Wins Order to Supply AU$970,000 Worth of HIV Self-Tests
Atomo Diagnostics (ASX:AT1) secured purchase orders from Viatris Healthcare worth AU$970,000 to supply HIV self-tests that are manufactured by Atomo under the Mylan brand for delivery to several low-
No Data